Proteina프로티나
468530 · KOSDAQ · ₩468530 · 프로티나
- Market cap
- ₩544B
- Enterprise value
- ₩527B
- P/E
- —
- P/B
- 24.0×
- Dividend yield
- 0.0%
- ROE
- −44.8%
- Net margin
- −704.4%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−59.2% from the high
₩15,500Today: ₩45,800 – ₩49,550₩120,100
Returns
- 1W+14.1%
- 1M+3.6%
- 3M+160.0%
- 6M−21.0%
- YTD−55.7%
- 1Y−3.5%
- Volume today
- 139,569
- 0.7× the 20-day average
- Traded today
- ₩6.7B
- Listed shares
- 11,105,148
- EPS (12 months)
- −₩915
- Earnings yield −1.9%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
+5.0% on Oct 27, 2026.
- • Foreign investors sold a net ₩919M that day
We found no news, filing or broker report explaining it yet. Moves without news happen; it may come later.
Possible reasons, not certainties. Not financial advice.
Signals
Quiet- BuzzQuietBuzz 41 of 100 (50 is a normal day for this stock).
- MomentumStrong22.5% over the last month; the price is above its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Sep 29: buy ₩46M at the close (1.0% of 20-day average trading value)
On its 43 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 0.0% of trading value and pointed the same way 0 of 43 times.
- -1× KODEX KOSDAQ150 Futures Inverse ₩23M
- 2× KODEX KOSDAQ150 Leverage ₩12M
- 2× TIGER KOSDAQ150 Leverage ₩6.7M
- 2× RISE KOSDAQ150 Futures Leverage ₩3.4M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
Proteina stock overview
Proteina (프로티나, KRX: 468530) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean PPI big-data firm that analyzes protein-protein interactions at the single-molecule level without purification, using its proprietary SPID platform (Pi-Chip, Pi-View and Pi-InSight systems). Its shares closed at ₩48,950 on Oct 27, 2026, up 5.04% on the day, giving it a market value of ₩544B.
Key facts
- Market cap
- ₩544B
- Sector
- Biotech & Pharma
- Latest price change
- +5.04%
- As of
- Oct 27, 2026
- Main business
- The company is a Korean PPI big-data firm that analyzes protein-protein interactions at the single-molecule level without purification, using its proprietary SPID platform (Pi-Chip, Pi-View and Pi-InSight systems).
Quick answers about Proteina
- What does Proteina do?
- The company is a Korean PPI big-data firm that analyzes protein-protein interactions at the single-molecule level without purification, using its proprietary SPID platform (Pi-Chip, Pi-View and Pi-InSight systems). Its commercial products are PPI PathFinder, a biomarker development solution used by multinational pharmaceutical companies in clinical trials, and PPI Landscape, an antibody drug discovery and optimization solution covering co-development and out-licensing of drug candidates. Its services span the drug development lifecycle.
- What is the market cap of Proteina?
- The market capitalisation of Proteina was ₩544B at the close on Oct 27, 2026.
- Who are the largest shareholders of Proteina?
- According to the latest official filings, the largest reported holders are Yoon Tae-young (25.63%, as of Aug 25, 2026); Korea Development Bank (4.60%, as of Sep 16, 2025); LB Investment (4.42%, as of Oct 13, 2025).
- When is the next earnings report from Proteina?
- Korean companies rarely announce results dates in advance. Based on when Proteina filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Proteina?
- Yes. The National Pension Service held 3.78% of Proteina shares as of Dec 31, 2025.
Company profile
The company is a Korean PPI big-data firm that analyzes protein-protein interactions at the single-molecule level without purification, using its proprietary SPID platform (Pi-Chip, Pi-View and Pi-InSight systems). Its commercial products are PPI PathFinder, a biomarker development solution used by multinational pharmaceutical companies in clinical trials, and PPI Landscape, an antibody drug discovery and optimization solution covering co-development and out-licensing of drug candidates. Its services span the drug development lifecycle.
Written by AI from the company's latest annual report.
- Korean name
- 프로티나
- Sector
- Biotech & Pharma
- CEO
- 윤태영
- Founded
- Aug 2015
- Listed
- Jul 2025
- Listed shares
- 11,105,148
- Fiscal year ends
- Month 12
- Website
- /www.proteina.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Insider shareholding reportAug 25, 2026
- Insider shareholding reportAug 25, 2026
- Insider shareholding reportAug 25, 2026
- Insider shareholding reportAug 25, 2026
- Insider shareholding reportAug 25, 2026
Titles in Korean until English translations are added.
Also known as: Proteina / 프로티나 / 468530 / KRX:468530
Source: KRX statistical information